Los Angeles Capital Management LLC Sells 4,410 Shares of ANI Pharmaceuticals, Inc. $ANIP

Los Angeles Capital Management LLC lessened its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 23.3% in the second quarter, Holdings Channel.com reports. The firm owned 14,513 shares of the specialty pharmaceutical company’s stock after selling 4,410 shares during the period. Los Angeles Capital Management LLC’s holdings in ANI Pharmaceuticals were worth $947,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of ANIP. Invesco Ltd. raised its position in ANI Pharmaceuticals by 1.0% in the 1st quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company’s stock valued at $13,361,000 after buying an additional 2,022 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of ANI Pharmaceuticals by 0.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company’s stock worth $15,959,000 after acquiring an additional 2,220 shares in the last quarter. State of Alaska Department of Revenue grew its stake in shares of ANI Pharmaceuticals by 10.0% during the 2nd quarter. State of Alaska Department of Revenue now owns 10,116 shares of the specialty pharmaceutical company’s stock worth $659,000 after acquiring an additional 920 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of ANI Pharmaceuticals by 22.4% in the first quarter. Victory Capital Management Inc. now owns 16,863 shares of the specialty pharmaceutical company’s stock valued at $1,129,000 after purchasing an additional 3,086 shares during the last quarter. Finally, Woodline Partners LP acquired a new stake in shares of ANI Pharmaceuticals in the first quarter valued at approximately $11,144,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

ANIP has been the subject of several recent research reports. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. JPMorgan Chase & Co. lifted their price target on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th. Guggenheim increased their price objective on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 21st. Finally, Weiss Ratings raised ANI Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $99.29.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $98.04, for a total value of $98,040.00. Following the completion of the sale, the senior vice president directly owned 60,186 shares of the company’s stock, valued at $5,900,635.44. This trade represents a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Antonio R. Pera sold 7,292 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $94.94, for a total value of $692,302.48. Following the transaction, the director owned 22,660 shares of the company’s stock, valued at $2,151,340.40. This represents a 24.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 147,281 shares of company stock valued at $13,309,804. Company insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $84.55 on Friday. The stock has a market cap of $1.83 billion, a P/E ratio of -109.80 and a beta of 0.54. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. The company has a fifty day moving average price of $92.99 and a two-hundred day moving average price of $78.04. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The company had revenue of $227.81 million for the quarter, compared to analyst estimates of $211.92 million. During the same period in the previous year, the business earned $1.34 EPS. ANI Pharmaceuticals’s revenue for the quarter was up 53.6% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.